美国英维利斯医疗诊断集团Inverness Medical Innovations Inc(IMA)
美国英维利斯医疗诊断集团 Inverness Medical Innovations （IMI）是一家在纽约证券交易所上市的世界体外快速诊断行业的领导者，总部位于美国波士顿Waltham。公司拥有世界一流的科研能力、生产基地和销售网络，经营家用、医用快速且高准确度的体外诊断试剂，曾被福布斯评为世界500个最具发展潜力的上市公司之一。

　　IMI的生产经营范围包括消费诊断、专业诊断、心血管疾病诊断、营养品及病人管理诊断产品五大领域。其中旗下闻名世界的子公司包括Unipath(英国原联合利华医疗诊断部)、Biosite (美国)、BBI(英国)、IMJ(日本、Determine HIV)、Panbio (澳大利亚)等四十余家。

　　IMI的妇女健康及家用快速诊断产品占有世界领先地位。在美国的市场份额占有率达75%，旗下产品Clearblue?系列已成为拥有数十亿美元身价的知名品牌。2006年底， IMI与美国宝洁公司(P&G) 合作，在瑞士日内瓦正式成立合资公司Swiss Precision Diagnostics（SPG），主要从事消费诊断产品在全球的研发与销售。在心脏病和凝结诊断领域，IMI同样拥有世界领先，独一无二的创新产品，并在全球进行销售。

　　目前，IMI为北美、欧洲、澳大利亚、日本、以色列等100多个国家提供高端的诊断测试产品。集团在注重产品的研发、市场营销运作的同时，囊括了几乎所有诊断测试产品的专利，包括快速分析测试技术及医学传感器等。

　　IMI致力于创造具有突破性的的产品，使人们能够在家中掌控自己的健康与生命！

 上海英伯肯医学生物技术有限公司Inverness Medical Shanghai Co., Ltd (IMSh)成立于2005年，是由美国英维利斯医学诊断集团Inverness Medical Innovations （IMI）控股，与上海生物芯片有限公司共同投资组建的医疗诊断制造企业.

　　IMSh在上海浦东张江高新技术开发区（张江药谷）建造了集现代化研发、生产和管理为一体的制造中心，占地5400平方米，为北美、欧洲、日本、澳大利亚、以色列等国家提供全方位、高品质的快速诊断试剂产品。公司遵守英维利斯集团严格的全球化生产管理和质量控制体系，严格使用符合GMP要求的生产厂房、专业生产设备和技术，规模化生产妇女健康(妊娠和排卵)系列及传染病系列快速诊断试剂产品。

　　目前，IMSh已经成为英维利斯集团在全球最主要的生产供应基地之一。产品质量满足ISO13485、中国GMP及美国FDA要求。经过多年不懈努力，我们已具备卓越的专业化研发和生产能力，建立了完善的服务体系和产品配送网络，在医疗诊断试剂的研发、生产、销售领域取得了长足的发展。

　　我们将继续着眼于用户所需，以卓越的产品质量满足客户的要求，为客户提供迅速、便捷和令人满意的服务，为促进中国及世界医疗保健事业的发展做出自己的贡献！

美艾利尔集团（Alere Inc）于2010年7月15日在得到股东大会的批准后，正式更名为此。其前身为美国英维利斯医疗诊断集团 Inverness Medical Innovations （IMI）

     

 At Inverness Medical Innovations, Inc., we believe that people all over the world want to be involved in their own care while remaining in their homes; and that when they do so they have an improved quality of life. By providing individuals with the tools and services that enable judgments to be made at home, under medical supervision, their health either improves or the progression of an existing chronic problem is delayed. Successful home management results in fewer urgent medical interactions and a reduction in hospital visits. This improvement in outcomes also leads to a reduction in health care costs, which provides a significant incentive to all payors.

A great deal of our research and development efforts are directed towards discovering new biomarkers that will allow better management of various chronic conditions. We establish these markers in clinical practice first, amongst relevant specialists and hospital based physicians. We then bring these new markers to the attention of internists and family practitioners for general use with their patients. Finally, as acceptance and understanding of the new marker expands, we develop an easy to use test that can be performed by a patient at home under remote medical supervision. This enables individuals to make changes in their medication or lifestyle from their homes, in consultation with their doctor, leading to better health.

Our primary areas of interest are in cardiology, women’s health, infectious disease, oncology and drugs of abuse, and we see exciting opportunities to develop innovative health management programs supported by advanced diagnostic and monitoring tools which will help people involved with these conditions to better look after themselves. However, we also expect to acquire technologies and products which over time will allow expansion to new medical issues, always focused on enabling individuals to take charge of their own health at home.